Biosynthetic machinery involved in aberrant glycosylation: Promising targets for developing of drugs against cancer

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Vasconcelos dos Santos, Andréia ^a   Oliveira, Isadora A ^a   Lucena, Miguel Clodomiro ^a   Mantuano, Natalia Rodrigues ^a   Whelan, Stephen A ^b   Dias, Wagner Barbosa ^a   Todeschini, Adriane Regina ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Glycans; Glycoconjugate; Glycosyltransferases; Hexosamine biosynthetic pathway; Inhibitors; N linked glycan; O linked glycan

Indexed keywords

EID: 84934284646     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00138     Document Type: Review

References (335)

1. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem (2011) 80:825-58. doi: 10.1146/annurev-biochem-060608-102511
2. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature (2014) 511(7509):319-25. doi:10.1038/nature13535
3. Alisson-Silva F, de Carvalho Rodrigues D, Vairo L, Asensi KD, Vasconcelos-dos-Santos A, Mantuano NR, et al. Evidences for the involvement of cell surface glycans in stem cell pluripotency and differentiation. Glycobiology (2014) 24(5):458-68. doi:10.1093/glycob/cwu012
4. Freire-de-Lima L, Alisson-Silva F, Carvalho ST, Takiya CM, Rodrigues MM, DosReis GA, et al. Trypanosoma cruzi subverts host cell sialylation and may compromise antigen-specific CD8+ T cell responses. J Biol Chem (2010) 285(18):13388-96. doi:10.1074/jbc.M109.096305
5. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer (2005) 5(7):526-42. doi:10.1038/nrc1649
6. Warburg O. On the origin of cancer cells. Science (1956) 123(3191):309-14. doi:10.1126/science.123.3191.309
7. Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (2011) 66(6):965-72. doi:10.1590/S1807-59322011000600008
8. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 2(9):683-93. doi:10.1038/nrc882
9. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene (2006) 25(34):4633-46. doi:10.1038/sj.onc.1209597
10. Muley P, Olinger A, Tummala H. 2-Deoxyglucose induces cell cycle arrest and apoptosisin colorectal cancer cells independent of its glycolysis inhibition. Nutr Cancer (2015) 67(3):514-22. doi:10.1080/01635581.2015.1002626
11. Jung DW, Kim WH, Park SH, Lee J, Kim J, Su D, et al. A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes. ACS Chem Biol (2013) 8(6):1271-82. doi:10.1021/cb300687k
12. Li S, Li Y, Hu R, Li W, Qiu H, Cai H, et al. The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells. Oncol Lett (2013) 5(2):717-21. doi:10.3892/ol.2012.1058
13. Datta S, Li J, Mahdi F, Jekabsons MB, Nagle DG, Zhou YD. Glycolysis inhibitor screening identifies the bis-geranylacylphloroglucinol protonophore moronone from Moronobea coccinea. J Nat Prod (2012) 75(12):2216-22. doi:10.1021/np300711e
14. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem (1991) 266(8):4706-12.
15. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 7(1):11-20. doi:10.1016/j.cmet.2007.10.002
16. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res (2013) 73(16):5277-87. doi:10.1158/0008-5472.CAN-13-0549
17. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High -glucose-induced transforming growth factor beta 1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest (1998) 101(1):160-9. doi:10.1172/JCI119875
18. Zhou L, Xue H, Yuan P, Ni J, Yu C, Huang Y, et al. Angiotensin AT1 receptor activation mediates high glucose-induced epithelial-mesenchymal transition in renal proximal tubular cells. Clin Exp Pharmacol Physiol (2010) 37(9):e152-7. doi:10.1111/j.1440-1681.2010.05421.x
19. Hakomori SI. Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett (2010) 584(9):1901-6. doi:10.1016/j.febslet.2009.10.065
20. Freire-de-Lima L, Gelfenbeyn K, Ding Y, Mandel U, Clausen H, Handa K, et al. Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proc Natl Acad Sci U S A (2011) 108(43):17690-5. doi:10.1073/pnas.1115191108
21. Alisson-Silva F, Freire-de-Lima L, Donadio JL, Lucena MC, Penha L, Sá-Diniz JN, et al. Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells. PLoS One (2013) 8(4):e60471. doi:10.1371/journal.pone.0060471
22. Dennis JW, Nabi IR, Demetriou M. Metabolism, cell surface organization, and disease. Cell (2009) 139(7):1229-41. doi:10.1016/j.cell.2009.12.008
23. O'Donnell N, Zachara NE, Hart GW, Marth JD. Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol (2004) 24(4):1680-90. doi:10.1128/MCB.24.4.1680-1690.2004
24. Dias WB, Hart GW. O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst (2007) 3(11):766-72. doi:10.1039/b704905f
25. Lowe DA, Emre M, Frey P, Kelly PH, Malanowski J, McAllister KH, et al. Progress in pharmacology of cerebral ischemia. Pharmazie (1994) 49(12):939-41.
26. Ostrowski A, van Aalten DM. Chemical tools to probe cellular O-GlcNAc signalling. Biochem J (2013) 456(1):1-12. doi:10.1042/BJ20131081
27. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature (2007) 446(7139):1017-22. doi:10.1038/nature05815
28. Whelan SA, Dias WB, Thiruneelakantapillai L, Lane MD, Hart GW. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem (2010) 285(8):5204-11. doi:10.1074/jbc.M109.077818
29. Dias WB, Cheung WD, Wang Z, Hart GW. Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc modification. J Biol Chem (2009) 284(32):21327-37. doi:10.1074/jbc.M109.007310
30. Dias WB, Cheung WD, Hart GW. O-GlcNAcylation of kinases. Biochem Biophys Res Commun (2012) 422(2):224-8. doi:10.1016/j.bbrc.2012.04.124
31. Slawson C, Hart GW. O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer (2011) 11(9):678-84. doi:10.1038/nrc3114
32. Ma Z, Vosseller K. O-GlcNAc in cancer biology. Amino Acids (2013) 45(4):719-33. doi:10.1007/s00726-013-1543-8
33. de Queiroz RM, Carvalho E, Dias WB. O-GlcNAcylation: the sweet side of the cancer. Front Oncol (2014) 4:132. doi:10.3389/fonc.2014.00132
34. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene (2010) 29(19):2831-42. doi:10.1038/onc.2010.41
35. Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M. Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med (2012) 12(1):61-5. doi:10.1007/s10238-011-0138-5
36. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta (2011) 1812(4):514-9. doi:10.1016/j.bbadis.2011.01.009
37. Ma ZY, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-kappa B activity in pancreatic cancer cells. J Biol Chem (2013) 288(21):15121-30. doi:10.1074/jbc.M113.470047
38. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem (2012) 287(14):11070-81. doi:10.1074/jbc.M111.302547
39. Lynch TP, Reginato MJ. O-GlcNAc transferase a sweet new cancer target. Cell Cycle (2011) 10(11):1712-3. doi:10.4161/cc.10.11.15561
40. Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol (2012) 29(2):985-93. doi:10.1007/s12032-011-9912-1
41. Rozanski W, Krzeslak A, Forma E, Brys M, Blewniewski M, Wozniak P, et al. Prediction of bladder cancer based on urinary content of MGEA5 and OGT mRNA level. Clin Lab (2012) 58(5-6):579-83.
42. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA 3rd, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science (2012) 337(6097):975-80. doi:10.1126/science.1222278
43. Slawson C, Copeland RJ, Hart GW. O-GlcNAc signaling: a metabolic link between diabetes and cancer? Trends Biochem Sci (2010) 35(10):547-55. doi:10.1016/j.tibs.2010.04.005
44. Park SY, Kim HS, Kim NH, Ji S, Cha SY, Kang JG, et al. Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. EMBO J (2010) 29(22):3787-96. doi:10.1038/emboj.2010.254
45. Jin FZ, Yu C, Zhao DZ, Wu MJ, Yang Z. A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells. Exp Cell Res (2013) 319(10):1482-90. doi:10.1016/j.yexcr.2013.03.013
46. Cheung WD, Sakabe K, Housley MP, Dias WB, Hart GW. O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J Biol Chem (2008) 283(49):33935-41. doi:10.1074/jbc.M806199200
47. Clarke AJ, Hurtado-Guerrero R, Pathak S, Schüttelkopf AW, Borodkin V, Shepherd SM, et al. Structural insights into mechanism and specificity of O-GlcNAc transferase. EMBO J (2008) 27(20):2780-8. doi:10.1038/emboj.2008.186
48. Lazarus MB, Nam Y, Jiang J, Sliz P, Walker S. Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature (2011) 469(7331):564-7. doi:10.1038/nature09638
49. Jiang J, Lazarus MB, Pasquina L, Sliz P, Walker S. A neutral diphosphate mimic crosslinks the active site of human O-GlcNAc transferase. Nat Chem Biol (2012) 8(1):72-7. doi:10.1038/nchembio.711
50. Schimpl M, Zheng X, Borodkin VS, Blair DE, Ferenbach AT, Schüttelkopf AW, et al. O-GlcNAc transferase invokes nucleotide sugar pyrophosphate participation in catalysis. Nat Chem Biol (2012) 8(12):969-74. doi:10.1038/nchembio.1108
51. Macauley MS, Vocadlo DJ. Increasing O-GlcNAc levels: an overview of small-molecule inhibitors of O-GlcNAcase. Biochim Biophys Acta (2010) 1800(2):107-21. doi:10.1016/j.bbagen.2009.07.028
52. Gloster TM, Zandberg WF, Heinonen JE, Shen DL, Deng L, Vocadlo DJ. Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. Nat Chem Biol (2011) 7(3):174-81. doi:10.1038/nchembio.520
53. Borodkin VS, Schimpl M, Gundogdu M, Rafie K, Dorfmueller HC, Robinson DA, et al. Bisubstrate UDP-peptide conjugates as human O-GlcNAc transferase inhibitors. Biochem J (2014) 457(3):497-502. doi:10.1042/BJ20131272
54. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A (2002) 99(16):10231-3. doi:10.1073/pnas.172380699
55. Laferte S, Dennis JW. Purification of two glycoproteins expressing beta 1-6 branched Asn-linked oligosaccharides from metastatic tumour cells. Biochem J (1989) 259(2):569-76.
56. Li WP, Zuber C, Heitz PU, Roth J. Cytochemical staining for beta 1,6 branching of asparagine-linked oligosaccharides in variants of metastatic human colon carcinoma cells. Am J Pathol (1994) 145(2):470-80.
57. Arnold JN, Saldova R, Galligan MC, Murphy TB, Mimura-Kimura Y, Telford JE, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res (2011) 10(4):1755-64. doi:10.1021/pr101034t
58. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 17(12):1344-56. doi:10.1093/glycob/cwm100
59. Saldova R, Reuben JM, Abd Hamid UM, Rudd PM, Cristofanilli M. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol (2011) 22(5):1113-9. doi:10.1093/annonc/mdq570
60. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology (2011) 21(2):195-205. doi:10.1093/glycob/cwq147
61. Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. Exploring the glycosylation of serum CA125. Int J Mol Sci (2013) 14(8):15636-54. doi:10.3390/ijms140815636
62. Zhao YP, Ruan CP, Wang H, Hu ZQ, Fang M, Gu X, et al. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer (2012) 118(3):639-50. doi:10.1002/cncr.26342
63. Liu L, Yan B, Huang J, Gu Q, Wang L, Fang M, et al. The identification and characterization of novel N-glycan-based biomarkers in gastric cancer. PLoS One (2013) 8(10):e77821. doi:10.1371/journal.pone.0077821
64. Liu X, Nie H, Zhang Y, Yao Y, Maitikabili A, Qu Y, et al. Cell surface-specific N-glycan profiling in breast cancer. PLoS One (2013) 8(8):e72704. doi:10.1371/journal.pone.0072704
65. Kamiyama T, Yokoo H, Furukawa J, Kurogochi M, Togashi T, Miura N, et al. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology (2013) 57(6):2314-25. doi:10.1002/hep.26262
66. Nouso K, Amano M, Ito YM, Miyahara K, Morimoto Y, Kato H, et al. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol (2013) 48(10):1171-9. doi:10.1007/s00535-012-0732-7
67. Wang X, He H, Zhang H, Chen W, Ji Y, Tang Z, et al. Clinical and prognostic implications of beta1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer. Cancer Sci (2013) 104(2):185-93. doi:10.1111/cas.12049
68. Sato C, Kim JH, Abe Y, Saito K, Yokoyama S, Kohda D. Characterization of the N-oligosaccharides attached to the atypical Asn-X-Cys sequence of recombinant human epidermal growth factor receptor. J Biochem (2000) 127(1):65-72. doi:10.1093/oxfordjournals.jbchem.a022585
69. Zheng M, Fang H, Hakomori S. Functional role of N-glycosylation in alpha 5 beta 1 integrin receptor. De-N-glycosylation induces dissociation or altered association of alpha 5 and beta 1 subunits and concomitant loss of fibronectin binding activity. J Biol Chem (1994) 269(16):12325-31.
70. Purchio AF, Cooper JA, Brunner AM, Lioubin MN, Gentry LE, Kovacina KS, et al. Identification of mannose 6-phosphate in two asparagine-linked sugar chains of recombinant transforming growth factor-beta 1 precursor. J Biol Chem (1988) 263(28):14211-5.
71. Patnaik SK, Potvin B, Carlsson S, Sturm D, Leffler H, Stanley P. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells. Glycobiology (2006) 16(4):305-17. doi:10.1093/glycob/cwj063
72. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol (2007) 7(4):255-66. doi:10.1038/nri2056
73. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, et al. Regulation of cytokine receptors by golgi N-glycan processing and endocytosis. Science (2004) 306(5693):120-4. doi:10.1126/science.1102109
74. Lajoie P, Partridge EA, Guay G, Goetz JG, Pawling J, Lagana A, et al. Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol (2007) 179(2):341-56. doi:10.1083/jcb.200611106
75. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature (2001) 409(6821):733-9. doi:10.1038/35055582
76. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW. Beta-1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res (1991) 51(2):718-23.
77. Boscher C, Zheng YZ, Lakshminarayan R, Johannes L, Dennis JW, Foster LJ, et al. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem (2012) 287(39):32940-52. doi:10.1074/jbc.M112.353334
78. Boscher C, Nabi IR. Galectin-3-and phospho-caveolin-1-dependent outside-in integrin signaling mediates the EGF motogenic response in mammary cancer cells. Mol Biol Cell (2013) 24(13):2134-45. doi:10.1091/mbc.E13-02-0095
79. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, et al. Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. J Proteome Res (2014) 13(5):2314-27. doi:10.1021/pr401092y
80. Banerjee DK. N-glycans in cell survival and death: cross-talk between glycosyltransferases. Biochim Biophys Acta (2012) 1820(9):1338-46. doi:10.1016/j.bbagen.2012.01.013
81. Schachter H. Complex N-glycans: the story of the "yellow brick road". Glycoconj J (2014) 31(1):1-5. doi:10.1007/s10719-013-9507-5
82. Yan Q, Lennarz WJ. Oligosaccharyltransferase: a complex multisubunit enzyme of the endoplasmic reticulum. Biochem Biophys Res Commun (1999) 266(3):684-9. doi:10.1006/bbrc.1999.1886
83. Elbein AD. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annu Rev Biochem (1987) 56:497-534. doi:10.1146/annurev.bi.56.070187.002433
84. Aebi M, Bernasconi R, Clerc S, Molinari M. N-glycan structures: recognition and processing in the ER. Trends Biochem Sci (2010) 35(2):74-82. doi:10.1016/j.tibs.2009.10.001
85. Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res (2008) 68(10):3803-9. doi:10.1158/0008-5472.CAN-07-6389
86. Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res (2010) 16(12):3205-14. doi:10.1158/1078-0432.CCR-09-3331
87. Siddals KW, Allen J, Sinha S, Canfield AE, Kalra PA, Gibson JM. Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization. J Biol Chem (2011) 286(19):16623-30. doi:10.1074/jbc.M110.202929
88. Hou H, Sun H, Lu P, Ge C, Zhang L, Li H, et al. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse xenograft models of human hepatocellular carcinoma. Mol Cancer Ther (2013) 12(12):2874-84. doi:10.1158/1535-7163.MCT-13-0201
89. de-Freitas-Junior JC, Bastos LG, Freire-Neto CA, Rocher BD, Abdelhay ES, Morgado-Díaz JA. N-glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells. J Cell Biochem (2012) 113(9):2957-66. doi:10.1002/jcb.24173
90. Yamamori T, Meike S, Nagane M, Yasui H, Inanami O. ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51. FEBS Lett (2013) 587(20):3348-53. doi:10.1016/j.febslet.2013.08.030
91. Banerjee A, Lang JY, Hung MC, Sengupta K, Banerjee SK, Baksi K, et al. Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem (2011) 286(33):29127-38. doi:10.1074/jbc.M110.169771
92. Elbein AD. Glycosylation inhibitors for N-linked glycoproteins. Methods Enzymol (1987) 138:661-709.
93. Irimura T, Gonzalez R, Nicolson GL. Effects of tunicamycin on B16-metastatic melanoma cell-surface glycoproteins and blood-borne arrest and survival properties. Cancer Res (1981) 41(9):3411-8.
94. Mareel MM, Dragonetti CH, Hooghe RJ, Bruyneel EA. Effect of inhibitors of glycosylation and carbohydrate processing on invasion of malignant mouse Mo4 cells in organ-culture. Clin Exp Metastasis (1985) 3(3):197-207. doi:10.1007/BF01786763
95. Pulverer G, Beuth J, Ko HL, Yassin A, Ohshima Y, Roszkowski K, et al. Glycoprotein modifications of sarcoma L-1 tumor-cells by tunicamycin, swainsonine, bromoconduritol or 1-desoxynojirimycin treatment inhibits their metastatic lung colonization in Balb/C-mice. J Cancer Res Clin Oncol (1988) 114(2):217-20. doi:10.1007/BF00417842
96. Guo R, Cheng L, Zhao Y, Zhang J, Liu C, Zhou H, et al. Glycogenes mediate the invasive properties and chemosensitivity of human hepatocarcinoma cells. Int J Biochem Cell Biol (2013) 45(2):347-58. doi:10.1016/j.biocel.2012.10.006
97. Matsumura K, Sakai C, Kawakami S, Yamashita F, Hashida M. Inhibition of cancer cell growth by GRP78 siRNA lipoplex via activation of unfolded protein response. Biol Pharm Bull (2014) 37(4):648-53. doi:10.1248/bpb.b13-00930
98. Humphries MJ, Matsumoto K, White SL, Olden K. Inhibition of experimental metastasis by castanospermine in mice - blockage of 2 distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Res (1986) 46(10):5215-22.
99. Leppa S, Heino J, Jalkanen M. Increased glycosylation of beta(1) integrins affects the interaction of transformed s115 mammary epithelial-cells with laminin-1. Cell Growth Differ (1995) 6(7):853-61.
100. Kang MS, Spencer JP, Elbein AD. Amphomycin inhibition of mannose and glcnac incorporation into lipid-linked saccharides. J Biol Chem (1978) 253(24):8860-6.
101. Nishimura Y. gem-diamine 1-N-iminosugars and related iminosugars, candidate of therapeutic agents for tumor metastasis. Curr Top Med Chem (2003) 3(5):575-91. doi:10.2174/1568026033452492
102. Schraen-Maschke S, Zanetta JP. Role of oligomannosidic N-glycans in the proliferation, adhesion and signalling of C6 glioblastoma cells. Biochimie (2003) 85(1-2):219-29. doi:10.1016/S0300-9084(03)00018-X
103. Sánchez-Fernández EM, Rísquez-Cuadro R, Chasseraud M, Ahidouch A, Ortiz Mellet C, Ouadid-Ahidouch H, et al. Synthesis of N-, S-, and C-glycoside castanospermine analogues with selective neutral alpha-glucosidase inhibitory activity as antitumour agents. Chem Commun (Camb) (2010) 46(29):5328-30. doi:10.1039/c0cc00446d
104. Allan G, Ouadid-Ahidouch H, Sanchez-Fernandez EM, Risquez-Cuadro R, Fernandez JM, Ortiz-Mellet C, et al. New castanospermine glycoside analogues inhibit breast cancer cell proliferation and induce apoptosis without affecting normal cells. PLoS One (2013) 8(10):e76411. doi:10.1371/journal.pone.0076411
105. Saul R, Chambers JP, Molyneux RJ, Elbein AD. Castanospermine, a tetrahydroxylated alkaloid that inhibits beta-glucosidase and beta-glucocerebrosidase. Arch Biochem Biophys (1983) 221(2):593-7. doi:10.1016/0003-9861(83)90181-9
106. Barker MK, Rose DR. Specificity of processing alpha-glucosidase I is guided by the substrate conformation crystallographic and in silico studies. J Biol Chem (2013) 288(19):13563-74. doi:10.1074/jbc.M113.460436
107. Sarkar M, Iliadi KG, Leventis PA, Schachter H, Boulianne GL. Neuronal expression of Mgat1 rescues the shortened life span of Drosophila Mgat11 null mutants and increases life span. Proc Natl Acad Sci U S A (2010) 107(21):9677-82. doi:10.1073/pnas.1004431107
108. Schachter H. Mgat1-dependent N-glycans are essential for the normal development of both vertebrate and invertebrate metazoans. Semin Cell Dev Biol (2010) 21(6):609-15. doi:10.1016/j.semcdb.2010.02.010
109. Schachter H. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochem Cell Biol (1986) 64(3):163-81. doi:10.1139/o86-026
110. Harpaz N, Schachter H. Control of glycoprotein synthesis. bovine colostrum UDP-N-acetylglucosamine:alpha-D-mannoside beta 2-N-acetylglucosaminyltransferase I. Separation from UDP-N-acetylglucosamine:alpha-D-mannoside beta 2-N-acetylglucosaminyltransferase II, partial purification, and substrate specificity. J Biol Chem (1980) 255(10):4885-93.
111. Yamashita K, Tachibana Y, Ohkura T, Kobata A. Enzymatic basis for the structural-changes of asparagine-linked sugar chains of membrane-glycoproteins of baby hamster-kidney cells induced by polyoma transformation. J Biol Chem (1985) 260(7):3963-9.
112. Buckhaults P, Chen L, Fregien N, Pierce M. Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J Biol Chem (1997) 272(31):19575-81. doi:10.1074/jbc.272.31.19575
113. Kang R, Saito H, Ihara Y, Miyoshi E, Koyama N, Sheng Y, et al. Transcriptional regulation of the N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1. J Biol Chem (1996) 271(43):26706-12. doi:10.1074/jbc.271.43.26706
114. Hatakeyama S, Amano M, Tobisawa Y, Yoneyama T, Tsuchiya N, Habuchi T, et al. Serum N-glycan alteration associated with renal cell carcinoma detected by high throughput glycan analysis. J Urol (2014) 191(3):805-13. doi:10.1016/j.juro.2013.10.052
115. Pinho SS, Seruca R, Gärtner F, Yamaguchi Y, Gu J, Taniguchi N, et al. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell Mol Life Sci (2011) 68(6):1011-20. doi:10.1007/s00018-010-0595-0
116. Pinho SS, Figueiredo J, Cabral J, Carvalho S, Dourado J, Magalhães A, et al. E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim Biophys Acta (2013) 1830(3):2690-700. doi:10.1016/j.bbagen.2012.10.021
117. Isaji T, Kariya Y, Xu Q, Fukuda T, Taniguchi N, Gu J. Functional roles of the bisecting GlcNAc in integrin-mediated cell adhesion. Methods Enzymol (2010) 480:445-59. doi:10.1016/S0076-6879(10)80019-9
118. Okada T, Ihara H, Ito R, Taniguchi N, Ikeda Y. Bidirectional N-acetylglucosamine transfer mediated by beta-1,4-N-acetylglucosaminyltransferase III. Glycobiology (2009) 19(4):368-74. doi:10.1093/glycob/cwn145
119. Zhao Y, Nakagawa T, Itoh S, Inamori K, Isaji T, Kariya Y, et al. N-acetylglucosaminyltransferase III antagonizes the effect of N-acetyl-glucosaminyltransferase V on alpha3beta1 integrin-mediated cell migration. J Biol Chem (2006) 281(43):32122-30. doi:10.1074/jbc.M607274200
120. Iijima J, Zhao Y, Isaji T, Kameyama A, Nakaya S, Wang X, et al. Cell-cell interaction-dependent regulation of N-acetylglucosaminyltransferase III and the bisected N-glycans in GE11 epithelial cells. Involvement of E-cadherin-mediated cell adhesion. J Biol Chem (2006) 281(19):13038-46. doi:10.1074/jbc.M601961200
121. Shigeta M, Shibukawa Y, Ihara H, Miyoshi E, Taniguchi N, Gu J. beta1,4-N-acetylglucosaminyltransferase III potentiates beta1 integrin-mediated neuritogenesis induced by serum deprivation in Neuro2a cells. Glycobiology (2006) 16(6):564-71. doi:10.1093/glycob/cwj100
122. Beheshti Zavareh R, Sukhai MA, Hurren R, Gronda M, Wang X, Simpson CD, et al. Suppression of cancer progression by MGAT1 shRNA knockdown. PLoS One (2012) 7(9):e43721. doi:10.1371/journal.pone.0043721
123. Isaji T, Gu J, Nishiuchi R, Zhao Y, Takahashi M, Miyoshi E, et al. Introduction of bisecting GlcNAc into integrin alpha(5)beta(1) reduces ligand binding and down-regulates cell adhesion and cell migration. J Biol Chem (2004) 279(19):19747-54. doi:10.1074/jbc.M311627200
124. Lau KS, Dennis JW. N-Glycans in cancer progression. Glycobiology (2008) 18(10):750-60. doi:10.1093/glycob/cwn071
125. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell (2007) 129(1):123-34. doi:10.1016/j.cell.2007.01.049
126. Pinho SS, Osório H, Nita-Lazar M, Gomes J, Lopes C, Gärtner F, et al. Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochem Biophys Res Commun (2009) 379(4):1091-6. doi:10.1016/j.bbrc.2009.01.024
127. Elbein AD. Inhibitors of the biosynthesis and processing of N-linked oligosaccharides. CRC Crit Rev Biochem (1984) 16(1):21-49. doi:10.3109/10409238409102805
128. Olden K, Breton P, Grzegorzewski K, Yasuda Y, Gause BL, Oredipe OA, et al. The potential importance of swainsonine in therapy for cancers and immunology. Pharmacol Ther (1991) 50(3):285-90. doi:10.1016/0163-7258(91)90046-O
129. Dennis JW. Effects of swainsonine and polyinosinic:polycytidylic acid on murine tumor cell growth and metastasis. Cancer Res (1986) 46(10):5131-6.
130. Humphries MJ, Matsumoto K, White SL, Olden K. Oligosaccharide modification by swainsonine treatment inhibits pulmonary colonization by B16-F10 murine melanoma cells. Proc Natl Acad Sci U S A (1986) 83(6):1752-6. doi:10.1073/pnas.83.6.1752
131. Korczak B, Dennis JW. Inhibition of N-linked oligosaccharide processing in tumor-cells is associated with enhanced tissue inhibitor of metalloproteinases (Timp) gene-expression. Int J Cancer (1993) 53(4):634-9. doi:10.1002/ijc.2910530418
132. Li Z, Huang Y, Dong F, Li W, Ding L, Yu G, et al. Swainsonine promotes apoptosis in human oesophageal squamous cell carcinoma cells in vitro and in vivo through activation of mitochondrial pathway. J Biosci (2012) 37(6):1005-16. doi:10.1007/s12038-012-9265-8
133. de Vries T, Knegtel RM, Holmes EH, Macher BA. Fucosyltransferases: structure/function studies. Glycobiology (2001) 11(10):119r-28r. doi:10.1093/glycob/11.10.119R
134. Muinelo-Romay L, Vázquez-Martín C, Villar-Portela S, Cuevas E, Gil-Martín E, Fernández-Briera A. Expression and enzyme activity of alpha(1,6)fucosyltransferase in human colorectal cancer. Int J Cancer (2008) 123(3):641-6. doi:10.1002/ijc.23521
135. Miyoshi E, Noda K, Ko JH, Ekuni A, Kitada T, Uozumi N, et al. Overexpression of alpha 1-6 fucosyltransferase in hepatoma cells suppresses intrahepatic metastasis after splenic injection in athymic mice. Cancer Res (1999) 59(9):2237-43.
136. Takahashi T, Ikeda Y, Miyoshi E, Yaginuma Y, Ishikawa M, Taniguchi N. alpha 1,6Fucosyltransferase is highly and specifically expressed in human ovarian serous adenocarcinomas. Int J Cancer (2000) 88(6):914-9. doi:10.1002/1097-0215(20001215)88:6<914::AID-IJC12>3.0.CO;2-1
137. Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, Yu CJ, et al. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci U S A (2013) 110(2):630-5. doi:10.1073/pnas.1220425110
138. Calderon H, Carpintero M, Garcia-Junceda E, Fernandez-Mayoralas A, Bastida A. Structure/activity relationship of carba- and C-fucopyranosides as inhibitors of an a 1,6-fucosyltransferase by molecular modeling and kinetic studies. Lett Org Chem (2005) 2(3):247-51. doi:10.2174/1570178053765393
139. Bastida A, Fernández-Mayoralas A, Gómez Arrayás R, Iradier F, Carretero JC, García-Junceda E. Heterologous over-expression of alpha-1,6-fucosyltransferase from Rhizobium sp.: application to the synthesis of the trisaccharide beta-D-GlcNAc(1 → 4)-[alpha-L-Fuc-(1 → 6)]-D-GlcNAc, study of the acceptor specificity and evaluation of polyhydroxylated indolizidines as inhibitors. Chemistry (2001) 7(11):2390-7. doi:10.1002/1521-3765(20010601)7:11<2390::AID-CHEM23900>3.0.CO;2-0
140. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep (2006) 7(6):599-604. doi:10.1038/sj.embor.7400705
141. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer (2004) 4(1):45-60. doi:10.1038/nrc1251
142. Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, et al. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int J Gynecol Cancer (2012) 22(4):531-8. doi:10.1097/IGC.0b013e3182473292
143. Akamine S, Nakagoe T, Sawai T, Tsuji T, Tanaka K, Hidaka S, et al. Differences in prognosis of colorectal cancer patients based on the expression of sialyl Lewisa, sialyl Lewisx and sialyl Tn antigens in serum and tumor tissue. Anticancer Res (2004) 24(4):2541-6.
144. Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, et al. alpha2,3-sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Int J Biochem Cell Biol (2013) 45(8):1748-57. doi:10.1016/j.biocel.2013.05.015
145. Schneider F, Kemmner W, Haensch W, Franke G, Gretschel S, Karsten U, et al. Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res (2001) 61(11):4605-11.
146. Ju T, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl (2011) 50(8):1770-91. doi:10.1002/anie.201002313
147. Hua D, Shen L, Xu L, Jiang Z, Zhou Y, Yue A, et al. Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer. Int J Mol Med (2012) 30(6):1267-74. doi:10.3892/ijmm.2012.1130
148. Liu J, Yang L, Jin M, Xu L, Wu S. Regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2. Mol Med Rep (2011) 4(6):1299-305. doi:10.3892/mmr.2011.569
149. Guo JM, Chen HL, Wang GM, Zhang YK, Narimatsu H. Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-12 in gastric and colonic cancer cell lines and in human colorectal cancer. Oncology (2004) 67(3-4):271-6. doi:10.1159/000081328
150. Ding MX, Wang HF, Wang JS, Zhan H, Zuo YG, Yang DL, et al. ppGalNAc T1 as a potential novel marker for human bladder cancer. Asian Pac J Cancer Prev (2012) 13(11):5653-7. doi:10.7314/APJCP.2012.13.11.5653
151. Onitsuka K, Shibao K, Nakayama Y, Minagawa N, Hirata K, Izumi H, et al. Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma. Cancer Sci (2003) 94(1):32-6. doi:10.1111/j.1349-7006.2003.tb01348.x
152. Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, et al. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer (2013) 109(2):472-81. doi:10.1038/bjc.2013.331
153. Yamamoto S, Nakamori S, Tsujie M, Takahashi Y, Nagano H, Dono K, et al. Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. Pathobiology (2004) 71(1):12-8. doi:10.1159/000072957
154. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, et al. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res (2010) 70(7):2759-69. doi:10.1158/0008-5472.CAN-09-3911
155. Park JH, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia (2011) 13(4):320-6. doi:10.1593/neo.101440
156. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem (2012) 287(17):14301-9. doi:10.1074/jbc.M111.337642
157. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 20(1):104-18. doi:10.1016/j.ccr.2011.05.027
158. Matsumoto Y, Zhang Q, Akita K, Nakada H, Hamamura K, Tokuda N, et al. pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen. Biochem Biophys Res Commun (2012) 419(1):7-13. doi:10.1016/j.bbrc.2012.01.086
159. Wang R, Yu C, Zhao D, Wu M, Yang Z. The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. Oncol Rep (2013) 30(2):667-76. doi:10.3892/or.2013.2493
160. Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, et al. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer (2010) 10:123. doi:10.1186/1471-2407-10-123
161. Tsuda N, Nonaka Y, Shichijo S, Yamada A, Ito M, Maeda Y, et al. UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour. Br J Cancer (2002) 87(9):1006-12. doi:10.1038/sj.bjc.6600593
162. Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, et al. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer (2011) 104(12):1882-9. doi:10.1038/bjc.2011.166
163. Freire T, Berois N, Sóñora C, Varangot M, Barrios E, Osinaga E. UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. Int J Cancer (2006) 119(6):1383-8. doi:10.1002/ijc.21959
164. Wragg S, Hagen FK, Tabak LA. Kinetic analysis of a recombinant UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase. J Biol Chem (1995) 270(28):16947-54. doi:10.1074/jbc.270.28.16947
165. Hatanaka K, Slama JT, Elbein AD. Synthesis of a new inhibitor of the UDP-GalNAc:polypeptide galactosaminyl transferase. Biochem Biophys Res Commun (1991) 175(2):668-72. doi:10.1016/0006-291X(91)91617-L
166. Kuan SF, Byrd JC, Basbaum C, Kim YS. Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells. J Biol Chem (1989) 264(32):19271-7.
167. Vavasseur F, Dole K, Yang J, Matta KL, Myerscough N, Corfield A, et al. O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur J Biochem (1994) 222(2):415-24. doi:10.1111/j.1432-1033.1994.tb18880.x
168. Delannoy P, Kim I, Emery N, De Bolos C, Verbert A, Degand P, et al. Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. Glycoconj J (1996) 13(5):717-26. doi:10.1007/BF00702335
169. Huang J, Byrd JC, Yoon WH, Kim YS. Effect of benzyl-alpha-GalNAc, an inhibitor of mucin glycosylation, on cancer-associated antigens in human colon cancer cells. Oncol Res (1992) 4(11-12):507-15.
170. Schafer A, Thiem J. Synthesis of novel donor mimetics of UDP-Gal, UDP-GlcNAc, and UDP-GalNAc as potential transferase inhibitors. J Org Chem (2000) 65(1):24-9. doi:10.1021/jo990766l
171. Busca P, Piller V, Piller F, Martin OR. Synthesis and biological evaluation of new UDP-GalNAc analogues for the study of polypeptide-alpha-GalNAc-transferases. Bioorg Med Chem Lett (2003) 13(11):1853-6. doi:10.1016/S0960-894X(03)00287-7
172. Hang HC, Yu C, Ten Hagen KG, Tian E, Winans KA, Tabak LA, et al. Small molecule inhibitors of mucin-type O-linked glycosylation from a uridine-based library. Chem Biol (2004) 11(3):337-45. doi:10.1016/j.chembiol.2004.02.023
173. Winans KA, Bertozzi CR. An inhibitor of the human UDP-GlcNAc 4-epimerase identified from a uridine-based library: a strategy to inhibit O-linked glycosylation. Chem Biol (2002) 9(1):113-29. doi:10.1016/S1074-5521(02)00093-5
174. Pouilly S, Piller V, Piller F. Metabolic glycoengineering through the mammalian GalNAc salvage pathway. FEBS J (2012) 279(4):586-98. doi:10.1111/j.1742-4658.2011.08448.x
175. Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res (2004) 64(19):7050-7. doi:10.1158/0008-5472.CAN-04-1921
176. Sewell R, Bäckström M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, et al. The ST6GalNAc-I sialyltransferase localizes throughout the golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem (2006) 281(6):3586-94. doi:10.1074/jbc.M511826200
177. Ikehara Y, Kojima N, Kurosawa N, Kudo T, Kono M, Nishihara S, et al. Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology (1999) 9(11):1213-24. doi:10.1093/glycob/9.11.1213
178. Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, et al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front Biosci (Elite Ed) (2011) 3:1443-55. doi:10.2741/345
179. Schuessler MH, Pintado S, Welt S, Real FX, Xu M, Melamed MR, et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int J Cancer (1991) 47(2):180-7. doi:10.1002/ijc.2910470204
180. Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett (2007) 249(2):157-70. doi:10.1016/j.canlet.2006.08.010
181. Ferreira JA, Videira PA, Lima L, Pereira S, Silva M, Carrascal M, et al. Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol Oncol (2013) 7(3):719-31. doi:10.1016/j.molonc.2013.03.001
182. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. STn and prognosis in breast cancer. Oncology (2001) 61(4):299-305. doi:10.1159/000055337
183. Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X, et al. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J (2001) 18(11-12):883-93. doi:10.1023/A:1022200525695
184. Julien S, Lagadec C, Krzewinski-Recchi MA, Courtand G, Le Bourhis X, Delannoy P. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res Treat (2005) 90(1):77-84. doi:10.1007/s10549-004-3137-3
185. Ozaki H, Matsuzaki H, Ando H, Kaji H, Nakanishi H, Ikehara Y, et al. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin Exp Metastasis (2012) 29(3):229-38. doi:10.1007/s10585-011-9445-1
186. Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T, et al. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem (2001) 276(14):11007-15. doi:10.1074/jbc.M006523200
187. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol (2001) 491:369-402. doi:10.1007/978-1-4615-1267-7_24
188. Baldus SE, Zirbes TK, Hanisch FG, Kunze D, Shafizadeh ST, Nolden S, et al. Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: a clinicopathologic study of 264 patients. Cancer (2000) 88(7):1536-43. doi:10.1002/(SICI)1097-0142(20000401)88:7<1536::AID-CNCR6>3.3.CO;2-N
189. Khaldoyanidi SK, Glinsky VV, Sikora L, Glinskii AB, Mossine VV, Quinn TP, et al. MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem (2003) 278(6):4127-34. doi:10.1074/jbc.M209590200
190. Solatycka A, Owczarek T, Piller F, Piller V, Pula B, Wojciech L, et al. MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 beta1,6-N-acetylglucosaminyltransferase and beta-galactoside alpha2,3-sialyltransferase. Glycobiology (2012) 22(8):1042-54. doi:10.1093/glycob/cws075
191. Hoffmann-Roder A, Kaiser A, Wagner S, Gaidzik N, Kowalczyk D, Westerlind U, et al. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue. Angew Chem Int Ed Engl (2010) 49(45):8498-503. doi:10.1002/anie.201003810
192. Inamdar SR, Savanur MA, Eligar SM, Chachadi VB, Nagre NN, Chen C, et al. The TF-antigen binding lectin from Sclerotium rolfsii inhibits growth of human colon cancer cells by inducing apoptosis in vitro and suppresses tumor growth in vivo. Glycobiology (2012) 22(9):1227-35. doi:10.1093/glycob/cws090
193. Aryal RP, Ju T, Cummings RD. The endoplasmic reticulum chaperone Cosmc directly promotes in vitro folding of T-synthase. J Biol Chem (2010) 285(4):2456-62. doi:10.1074/jbc.M109.065169
194. Aryal RP, Ju T, Cummings RD. Tight complex formation between Cosmc chaperone and its specific client non-native T-synthase leads to enzyme activity and client-driven dissociation. J Biol Chem (2012) 287(19):15317-29. doi:10.1074/jbc.M111.312587
195. Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science (2006) 314(5797):304-8. doi:10.1126/science.1129200
196. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res (2008) 68(6):1636-46. doi:10.1158/0008-5472.CAN-07-2345
197. Mi R, Song L, Wang Y, Ding X, Zeng J, Lehoux S, et al. Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen. J Biol Chem (2012) 287(49):41523-33. doi:10.1074/jbc.M112.371989
198. Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH, Hu RH, et al. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res (2013) 73(17):5580-90. doi:10.1158/0008-5472.CAN-13-0869
199. Barrow H, Tam B, Duckworth CA, Rhodes JM, Yu LG. Suppression of core 1 Gal-transferase is associated with reduction of TF and reciprocal increase of Tn, sialyl-Tn and core 3 glycans in human colon cancer cells. PLoS One (2013) 8(3):e59792. doi:10.1371/journal.pone.0059792
200. Yousefi S, Higgins E, Daoling Z, Pollex-Krüger A, Hindsgaul O, Dennis JW. Increased UDP-GlcNAc:Gal beta 1-3GaLNAc-R (GlcNAc to GaLNAc) beta-1, 6-N-acetylglucosaminyltransferase activity in metastatic murine tumor cell lines. Control of polylactosamine synthesis. J Biol Chem (1991) 266(3):1772-82.
201. Hagisawa S, Ohyama C, Takahashi T, Endoh M, Moriya T, Nakayama J, et al. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology (2005) 15(10):1016-24. doi:10.1093/glycob/cwi086
202. Hatakeyama S, Kyan A, Yamamoto H, Okamoto A, Sugiyama N, Suzuki Y, et al. Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor. Int J Cancer (2010) 127(5):1052-9. doi:10.1002/ijc.25117
203. Miyamoto T, Suzuki A, Asaka R, Ishikawa K, Yamada Y, Kobara H, et al. Immunohistochemical expression of core 2 beta1,6-N-acetylglucosaminyl transferase 1 (C2GnT1) in endometrioid-type endometrial carcinoma: a novel potential prognostic factor. Histopathology (2013) 62(7):986-93. doi:10.1111/his.12107
204. Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T, et al. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int J Oncol (2012) 40(6):1831-8. doi:10.3892/ijo.2012.1411
205. Brockhausen I, Kuhns W, Schachter H, Matta KL, Sutherland DR, Baker MA. Biosynthesis of O-glycans in leukocytes from normal donors and from patients with leukemia: increase in O-glycan core 2 UDP-GlcNAc:Gal beta 3 GalNAc alpha-R (GlcNAc to GalNAc) beta(1-6)-N-acetylglucosaminyltransferase in leukemic cells. Cancer Res (1991) 51(4):1257-63.
206. Nguyen JT, Evans DP, Galvan M, Pace KE, Leitenberg D, Bui TN, et al. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J Immunol (2001) 167(10):5697-707. doi:10.4049/jimmunol.167.10.5697
207. Cabrera PV, Amano M, Mitoma J, Chan J, Said J, Fukuda M, et al. Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death. Blood (2006) 108(7):2399-406. doi:10.1182/blood-2006-04-018556
208. Huang MC, Chen HY, Huang HC, Huang J, Liang JT, Shen TL, et al. C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells. Oncogene (2006) 25(23):3267-76. doi:10.1038/sj.onc.1209350
209. Maemura K, Fukuda M. Poly-N-acetyllactosaminyl O-glycans attached to leukosialin. The presence of sialyl Le(x) structures in O-glycans. J Biol Chem (1992) 267(34):24379-86.
210. Bierhuizen MF, Maemura K, Fukuda M. Expression of a differentiation antigen and poly-N-acetyllactosaminyl O-glycans directed by a cloned core 2 beta-1,6-N-acetylglucosaminyltransferase. J Biol Chem (1994) 269(6):4473-9.
211. Hindsgaul O, Kaur KJ, Srivastava G, Blaszczyk-Thurin M, Crawley SC, Heerze LD, et al. Evaluation of deoxygenated oligosaccharide acceptor analogs as specific inhibitors of glycosyltransferases. J Biol Chem (1991) 266(27):17858-62.
212. Kuhns W, Rutz V, Paulsen H, Matta KL, Baker MA, Barner M, et al. Processing O-glycan core 1, Gal beta 1-3GalNAc alpha-R. Specificities of core 2, UDP-GlcNAc: Gal beta 1-3 GalNAc-R(GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase and CMP-sialic acid: Gal beta 1-3GalNAc-R alpha 3-sialyltransferase. Glycoconj J (1993) 10(5):381-94. doi:10.1007/BF00731043
213. Toki D, Granovsky MA, Reck F, Kuhns W, Baker MA, Matta KL, et al. Inhibition of UDP-GlcNAc:Gal beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from acute myeloid leukaemia cells by photoreactive nitrophenyl substrate derivatives. Biochem Biophys Res Commun (1994) 198(2):417-23. doi:10.1006/bbrc.1994.1061
214. Almeida R, Amado M, David L, Levery SB, Holmes EH, Merkx G, et al. A family of human beta4-galactosyltransferases. Cloning and expression of two novel UDP-galactose:beta-n-acetylglucosamine beta1, 4-galactosyltransferases, beta4Gal-T2 and beta4Gal-T3. J Biol Chem (1997) 272(51):31979-91. doi:10.1074/jbc.272.51.31979
215. Shaper NL, Meurer JA, Joziasse DH, Chou TD, Smith EJ, Schnaar RL, et al. The chicken genome contains two functional nonallelic beta1,4-galactosyltransferase genes. Chromosomal assignment to syntenic regions tracks fate of the two gene lineages in the human genome. J Biol Chem (1997) 272(50):31389-99. doi:10.1074/jbc.272.50.31389
216. Sato T, Furukawa K, Bakker H, Van den Eijnden DH, Van Die I. Molecular cloning of a human cDNA encoding beta-1,4-galactosyltransferase with 37% identity to mammalian UDP-Gal:GlcNAc beta-1,4-galactosyltransferase. Proc Natl Acad Sci U S A (1998) 95(2):472-7. doi:10.1073/pnas.95.2.472
217. Lo NW, Shaper JH, Pevsner J, Shaper NL. The expanding beta 4-galactosyltransferase gene family: messages from the databanks. Glycobiology (1998) 8(5):517-26. doi:10.1093/glycob/8.5.517
218. Schwientek T, Almeida R, Levery SB, Holmes EH, Bennett E, Clausen H. Cloning of a novel member of the UDP-galactose:beta-N-acetylglucosamine beta1,4-galactosyltransferase family, beta4Gal-T4, involved in glycosphingolipid biosynthesis. J Biol Chem (1998) 273(45):29331-40. doi:10.1074/jbc.273.45.29331
219. Nomura T, Takizawa M, Aoki J, Arai H, Inoue K, Wakisaka E, et al. Purification, cDNA cloning, and expression of UDP-Gal: glucosylceramide beta-1,4-galactosyltransferase from rat brain. J Biol Chem (1998) 273(22):13570-7. doi:10.1074/jbc.273.22.13570
220. Ujita M, McAuliffe J, Schwientek T, Almeida R, Hindsgaul O, Clausen H, et al. Synthesis of poly-N-acetyllactosamine in core 2 branched O-glycans. The requirement of novel beta-1,4-galactosyltransferase IV and beta-1,3-n-acetylglucosaminyltransferase. J Biol Chem (1998) 273(52):34843-9. doi:10.1074/jbc.273.52.34843
221. Almeida R, Levery SB, Mandel U, Kresse H, Schwientek T, Bennett EP, et al. Cloning and expression of a proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I. A seventh member of the human beta4-galactosyltransferase gene family. J Biol Chem (1999) 274(37):26165-71. doi:10.1074/jbc.274.37.26165
222. Sasaki K, Kurata-Miura K, Ujita M, Angata K, Nakagawa S, Sekine S, et al. Expression cloning of cDNA encoding a human beta-1,3-N-acetylglucosaminyltransferase that is essential for poly-N-acetyllactosamine synthesis. Proc Natl Acad Sci U S A (1997) 94(26):14294-9. doi:10.1073/pnas.94.26.14294
223. Zhou D, Dinter A, Gutiérrez Gallego R, Kamerling JP, Vliegenthart JF, Berger EG, et al. A beta-1,3-N-acetylglucosaminyltransferase with poly-N-acetyllactosamine synthase activity is structurally related to beta-1,3-galactosyltransferases. Proc Natl Acad Sci U S A (1999) 96(2):406-11. doi:10.1073/pnas.96.2.406
224. Shiraishi N, Natsume A, Togayachi A, Endo T, Akashima T, Yamada Y, et al. Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family. J Biol Chem (2001) 276(5):3498-507. doi:10.1074/jbc.M004800200
225. Beum PV, Cheng PW. Biosynthesis and function of beta 1,6 branched mucin-type glycans. Adv Exp Med Biol (2001) 491:279-312.
226. Bierhuizen MF, Mattei MG, Fukuda M. Expression of the developmental I antigen by a cloned human cDNA encoding a member of a beta-1,6-N-acetylglucosaminyltransferase gene family. Genes Dev (1993) 7(3):468-78. doi:10.1101/gad.7.3.468
227. Inaba N, Hiruma T, Togayachi A, Iwasaki H, Wang XH, Furukawa Y, et al. A novel I-branching beta-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood (2003) 101(7):2870-6. doi:10.1182/blood-2002-09-2838
228. Yeh JC, Ong E, Fukuda M. Molecular cloning and expression of a novel beta-1, 6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches. J Biol Chem (1999) 274(5):3215-21. doi:10.1074/jbc.274.5.3215
229. Ito N, Yokota M, Nagaike C, Morimura Y, Hatake K, Matsunaga T. Histochemical demonstration and analysis of poly-N-acetyllactosamine structures in normal and malignant human tissues. Histol Histopathol (1996) 11(1):203-14.
230. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD. Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis (2005) 22(1):11-24. doi:10.1007/s10585-005-2036-2
231. Kawakami H, Ito M, Miura Y, Hirano H. Involvement of N-acetyl-lactosamine-containing sugar structures in the liver metastasis of mouse colon carcinoma (colon 26) cells. J Gastroenterol Hepatol (1994) 9(6):567-71. doi:10.1111/j.1440-1746.1994.tb01562.x
232. Okamoto T, Yoneyama MS, Hatakeyama S, Mori K, Yamamoto H, Koie T, et al. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. Mol Med Rep (2013) 7(2):359-64. doi:10.3892/mmr.2012.1189
233. Srinivasan N, Bane SM, Ahire SD, Ingle AD, Kalraiya RD. Poly N-acetyll-actosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J (2009) 26(4):445-56. doi:10.1007/s10719-008-9194-9
234. Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol (2012) 132(2):410-20. doi:10.1038/jid.2011.335
235. Xu S, Zhu X, Zhang S, Yin S, Zhou L, Chen C, et al. Over-expression of beta-1,4-galactosyltransferase I, II, and V in human astrocytoma. J Cancer Res Clin Oncol (2001) 127(8):502-6. doi:10.1007/s004320100246
236. Chen WS, Chang HY, Li CP, Liu JM, Huang TS. Tumor beta-1,4-galactosyltransferase IV overexpression is closely associated with colorectal cancer metastasis and poor prognosis. Clin Cancer Res (2005) 11(24 Pt 1):8615-22. doi:10.1158/1078-0432.CCR-05-1006
237. Chang HH, Chen CH, Chou CH, Liao YF, Huang MJ, Chen YH, et al. beta-1,4-galactosyltransferase III enhances invasive phenotypes via beta1-integrin and predicts poor prognosis in neuroblastoma. Clin Cancer Res (2013) 19(7):1705-16. doi:10.1158/1078-0432.CCR-12-2367
238. Lopez LC, Maillet CM, Oleszkowicz K, Shur BD. Cell surface and golgi pools of beta-1,4-galactosyltransferase are differentially regulated during embryonal carcinoma cell differentiation. Mol Cell Biol (1989) 9(6):2370-7.
239. Shur BD. Glycosyltransferases as cell adhesion molecules. Curr Opin Cell Biol (1993) 5(5):854-63. doi:10.1016/0955-0674(93)90035-O
240. Johnson FM, Shur BD. The level of cell surface beta1,4-galactosyltransferase I influences the invasive potential of murine melanoma cells. J Cell Sci (1999) 112(Pt 16):2785-95.
241. Choi HJ, Chung TW, Kim CH, Jeong HS, Joo M, Youn B, et al. Estrogen induced beta-1,4-galactosyltransferase 1 expression regulates proliferation of human breast cancer MCF-7 cells. Biochem Biophys Res Commun (2012) 426(4):620-5. doi:10.1016/j.bbrc.2012.08.140
242. Zhou H, Zhang Z, Liu C, Jin C, Zhang J, Miao X, et al. B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line. IUBMB Life (2012) 64(11):889-900. doi:10.1002/iub.1080
243. Vaghefi MM, Bernacki RJ, Dalley NK, Wilson BE, Robins RK. Synthesis of glycopyranosylphosphonate analogues of certain natural nucleoside diphosphate sugars as potential inhibitors of glycosyltransferases. J Med Chem (1987) 30(8):1383-91. doi:10.1021/jm00391a021
244. Vaghefi MM, Bernacki RJ, Hennen WJ, Robins RK. Synthesis of certain nucleoside methylenediphosphonate sugars as potential inhibitors of glycosyltransferases. J Med Chem (1987) 30(8):1391-9. doi:10.1021/jm00391a021
245. Wang R, Steensma DH, Takaoka Y, Yun JW, Kajimoto T, Wong CH. A search for pyrophosphate mimics for the development of substrates and inhibitors of glycosyltransferases. Bioorg Med Chem (1997) 5(4):661-72. doi:10.1016/S0968-0896(97)00005-9
246. Hashimoto H, Endo T, Kajihara Y. Synthesis of the first tricomponent bisubstrate analogue that exhibits potent inhibition against GlcNAc:beta-1,4-galactosyltransferase. J Org Chem (1997) 62(7):1914-5. doi:10.1021/jo962235s
247. Chung SJ, Takayama S, Wong CH. Acceptor substrate-based selective inhibition of galactosyltransferases. Bioorg Med Chem Lett (1998) 8(23):3359-64. doi:10.1016/S0960-894X(98)00618-0
248. Takayama S, Chung SJ, Igarashi Y, Ichikawa Y, Sepp A, Lechler RI, et al. Selective inhibition of beta-1,4- and alpha-1,3-galactosyltransferases: donor sugar-nucleotide based approach. Bioorg Med Chem (1999) 7(2):401-9. doi:10.1016/S0968-0896(98)00249-1
249. Gastinel LN, Cambillau C, Bourne Y. Crystal structures of the bovine beta4galactosyltransferase catalytic domain and its complex with uridine diphosphogalactose. EMBO J (1999) 18(13):3546-57. doi:10.1093/emboj/18.13.3546
250. Ramakrishnan B, Balaji PV, Qasba PK. Crystal structure of beta1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol (2002) 318(2):491-502. doi:10.1016/S0022-2836(02)00020-7
251. Takaya K, Nagahori N, Kurogochi M, Furuike T, Miura N, Monde K, et al. Rational design, synthesis, and characterization of novel inhibitors for human beta1,4-galactosyltransferase. J Med Chem (2005) 48(19):6054-65. doi:10.1021/jm0504297
252. Brockhausen I, Benn M, Bhat S, Marone S, Riley JG, Montoya-Peleaz P, et al. UDP-Gal: GlcNAc-R beta1,4-galactosyltransferase - a target enzyme for drug design. Acceptor specificity and inhibition of the enzyme. Glycoconj J (2006) 23(7-8):525-41. doi:10.1007/s10719-006-7153-x
253. Gao Y, Lazar C, Szarek WA, Brockhausen I. Specificity of beta1,4-galactosyltransferase inhibition by 2-naphthyl 2-butanamido-2-deoxy-1-thio-beta-D-glucopyranoside. Glycoconj J (2010) 27(7-9):673-84. doi:10.1007/s10719-010-9312-3
254. Ishida H, Togayachi A, Sakai T, Iwai T, Hiruma T, Sato T, et al. A novel beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer. FEBS Lett (2005) 579(1):71-8. doi:10.1016/j.febslet.2004.11.037
255. Zhang H, Meng F, Wu S, Kreike B, Sethi S, Chen W, et al. Engagement of I-branching beta-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-beta signaling. Cancer Res (2011) 71(14):4846-56. doi:10.1158/0008-5472.CAN-11-0414
256. Kawashima H, Yamamoto K, Osawa T, Irimura T. Purification and characterization of UDP-GlcNAc:Gal beta 1-4Glc(NAc) beta-1,3-N-acetylglucosaminyltransferase (poly-N-acetyllactosamine extension enzyme) from calf serum. J Biol Chem (1993) 268(36):27118-26.
257. Sakamoto Y, Taguchi T, Tano Y, Ogawa T, Leppänen A, Kinnunen M, et al. Purification and characterization of UDP-GlcNAc:Galbeta1-4GlcNAcbeta1-3*Galbeta1-4Glc(NAc)-R(GlcNAc to *Gal) beta1,6N-acetylglucosaminyltransferase from hog small intestine. J Biol Chem (1998) 273(42):27625-32. doi:10.1074/jbc.273.42.27625
258. Tedaldi LM, Pierce M, Wagner GK. Optimised chemical synthesis of 5-substituted UDP-sugars and their evaluation as glycosyltransferase inhibitors. Carbohydr Res (2012) 364:22-7. doi:10.1016/j.carres.2012.10.009
259. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS (2000) 108(1):1-28. doi:10.1034/j.1600-0463.2000.d01-1.x
260. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clément M. ABH and Lewis histo-blood group antigens in cancer. APMIS (2001) 109(1):9-31. doi:10.1111/j.1600-0463.2001.tb00011.x
261. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta (1999) 1473(1):247-66. doi:10.1016/S0304-4165(99)00183-X
262. Yoshida A, Kumazaki T, Davé V, Blank J, Dzik WH. Suppressed expression of blood group B antigen and blood group galactosyltransferase in a preleukemic subject. Blood (1985) 66(4):990-2.
263. Orntoft TF, Wolf H, Watkins WM. Activity of the human blood group ABO, Se, H, Le, and X gene-encoded glycosyltransferases in normal and malignant bladder urothelium. Cancer Res (1988) 48(15):4427-33.
264. Mandel U, Langkilde NC, Orntoft TF, Therkildsen MH, Karkov J, Reibel J, et al. Expression of histo-blood-group-A/B-gene-defined glycosyltransferases in normal and malignant epithelia: correlation with A/B-carbohydrate expression. Int J Cancer (1992) 52(1):7-12. doi:10.1002/ijc.2910520103
265. León-Atance P, Moreno-Mata N, González-Aragoneses F, Cañizares-Carretero MÁ, Poblet-Martínez E, Genovés-Crespo M, et al. Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer. Arch Bronconeumol (2012) 48(2):49-54. doi:10.1016/j.arbres.2011.10.003
266. Fukushima K, Satoh T, Baba S, Yamashita K. alpha 1,2-fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology (2010) 20(4):452-60. doi:10.1093/glycob/cwp197
267. Moehler TM, Sauer S, Witzel M, Andrulis M, Garcia-Vallejo JJ, Grobholz R, et al. Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis. J Cell Physiol (2008) 215(1):27-36. doi:10.1002/jcp.21285
268. Goupille C, Hallouin F, Meflah K, Le Pendu J. Increase of rat colon carcinoma cells tumorigenicity by alpha(1-2) fucosyltransferase gene transfection. Glycobiology (1997) 7(2):221-9. doi:10.1093/glycob/7.2.221
269. Marionneau S, Bureau V, Goupille C, Hallouin F, Rocher J, Vaydie B, et al. Susceptibility of rat colon carcinoma cells to lymphokine activated killer-mediated cytotoxicity is decreased by alpha 1,2-fucosylation. Int J Cancer (2000) 86(5):713-7. doi:10.1002/(SICI)1097-0215(20000601)86:5<713::AID-IJC17>3.0.CO;2-V
270. Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood (2005) 105(12):4759-66. doi:10.1182/blood-2004-11-4307
271. Mollicone R, Candelier JJ, Mennesson B, Couillin P, Venot AP, Oriol R. Five specificity patterns of (1 - - 3)-alpha-L-fucosyltransferase activity defined by use of synthetic oligosaccharide acceptors. Differential expression of the enzymes during human embryonic development and in adult tissues. Carbohydr Res (1992) 228(1):265-76. doi:10.1016/S0008-6215(00)90564-0
272. Yan L, Lin B, Gao L, Gao S, Liu C, Wang C, et al. Lewis (y) antigen overexpression increases the expression of MMP-2 and MMP-9 and invasion of human ovarian cancer cells. Int J Mol Sci (2010) 11(11):4441-52. doi:10.3390/ijms11114441
273. Isla Larrain M, Demichelis S, Crespo M, Lacunza E, Barbera A, Cretón A, et al. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with mucin 1 (MUC1). J Exp Clin Cancer Res (2009) 28:121. doi:10.1186/1756-9966-28-121
274. Myers RB, Srivastava S, Grizzle WE. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J Urol (1995) 153(5):1572-4. doi:10.1097/00005392-199505000-00061
275. Waldock A, Ellis IO, Armitage N, Turner DR, Hardcastle JD, Embleton J. Differential expression of the Lewis Y antigen defined by monoclonal antibody C14/1/46/10 in colonic polyps. Cancer (1989) 64(2):414-21. doi:10.1002/1097-0142(19890715)64:2<414::AID-CNCR2820640213>3.0.CO;2-0
276. Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother (2009) 32(3):292-301. doi:10.1097/CJI.0b013e31819b7c8e
277. Yuriev E, Farrugia W, Scott AM, Ramsland PA. Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer. Immunol Cell Biol (2005) 83(6):709-17. doi:10.1111/j.1440-1711.2005.01374.x
278. Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer (2000) 87(1):79-85. doi:10.1002/1097-0215(20000701)87:1<79::AID-IJC12>3.0.CO;2-L
279. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res (2007) 13(14):4170-7. doi:10.1158/1078-0432.CCR-06-2949
280. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol (2000) 18(11):2282-92.
281. Motzer RJ, Reuter VE, Cordon-Cardo C, Bosl GJ. Blood group-related antigens in human germ cell tumors. Cancer Res (1988) 48(18):5342-7.
282. Kawai S, Kato S, Imai H, Okada Y, Ishioka C. Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87. Oncol Rep (2013) 29(1):13-20. doi:10.3892/or.2012.2120
283. Palcic MM, Heerze LD, Srivastava OP, Hindsgaul O. A bisubstrate analog inhibitor for alpha-(1-]2)-fucosyltransferase. J Biol Chem (1989) 264(29):17174-81.
284. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J (1997) 14(5):577-84. doi:10.1023/A:1018532409041
285. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J (1997) 14(5):569-76. doi:10.1023/A:1018580324971
286. Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer (1995) 75(8):2051-6. doi:10.1002/1097-0142(19950415)75:8<2051::AID-CNCR2820750804>3.0.CO;2-4
287. Iwai K, Ishikura H, Kaji M, Sugiura H, Ishizu A, Takahashi C, et al. Importance of E-selectin (ELAM-1) and sialyl Lewis(a) in the adhesion of pancreatic carcinoma cells to activated endothelium. Int J Cancer (1993) 54(6):972-7. doi:10.1002/ijc.2910540618
288. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res (1993) 53(2):354-61.
289. Jørgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res (1995) 55(9):1817-9.
290. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res (1993) 53(15):3632-7.
291. Ogawa J, Tsurumi T, Yamada S, Koide S, Shohtsu A. Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer (1994) 73(4):1177-83. doi:10.1002/1097-0142(19940215)73:4<1177::AID-CNCR2820730409>3.0.CO;2-0
292. Renkonen J, Paavonen T, Renkonen R. Endothelial and -epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer (1997) 74(3):296-300. doi:10.1002/(SICI)1097-0215(19970620)74:3<296::AID-IJC11>3.0.CO;2-A
293. Ravindranath MH, Amiri AA, Bauer PM, Kelley MC, Essner R, Morton DL. Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma. Cancer (1997) 79(9):1686-97. doi:10.1002/(SICI)1097-0142(19970501)79:9<1686::AID-CNCR8>3.0.CO;2-A
294. Kannagi R. Carbohydrate antigen sialyl Lewis a - its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J (2007) 30(3):189-209.
295. Majuri ML, Niemelä R, Tiisala S, Renkonen O, Renkonen R. Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Int J Cancer (1995) 63(4):551-9. doi:10.1002/ijc.2910630416
296. Tsuji S, Datta AK, Paulson JC. Systematic nomenclature for sialyltransferases. Glycobiology (1996) 6(7):v-vii.
297. Kono M, Takashima S, Liu H, Inoue M, Kojima N, Lee YC, et al. Molecular cloning and functional expression of a fifth-type alpha 2,3-sialyltransferase (mST3Gal V: GM3 synthase). Biochem Biophys Res Commun (1998) 253(1):170-5. doi:10.1006/bbrc.1998.9768
298. Okajima T, Fukumoto S, Ito H, Kiso M, Hirabayashi Y, Urano T, et al. Molecular cloning of brain-specific GD1alpha synthase (ST6GalNAc V) containing CAG/Glutamine repeats. J Biol Chem (1999) 274(43):30557-62. doi:10.1074/jbc.274.43.30557
299. Pérez-Garay M, Arteta B, Pagès L, de Llorens R, de Bolòs C, Vidal-Vanaclocha F, et al. alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS One (2010) 5(9):e12524. doi:10.1371/journal.pone.0012524
300. Bernacki RJ. Regulation of rat-liver glycoprotein: N-acetylneuraminic acid transferase activity by pyrimidine nucleotides. Eur J Biochem (1975) 58(2):477-81. doi:10.1111/j.1432-1033.1975.tb02395.x
301. Kijima-Suda I, Miyamoto Y, Toyoshima S, Itoh M, Osawa T. Inhibition of experimental pulmonary metastasis of mouse colon adenocarcinoma 26 sublines by a sialic acid:nucleoside conjugate having sialyltransferase inhibiting activity. Cancer Res (1986) 46(2):858-62.
302. Kijima I, Ezawa K, Toyoshima S, Furuhata K, Ogura H, Osawa T. Induction of suppressor T cells by neuraminic acid derivatives. Chem Pharm Bull (Tokyo) (1982) 30(9):3278-83. doi:10.1248/cpb.30.3278
303. Skropeta D, Schwörer R, Haag T, Schmidt RR. Asymmetric synthesis and affinity of potent sialyltransferase inhibitors based on transition-state analogues. Glycoconj J (2004) 21(5):205-19. doi:10.1023/B:GLYC.0000045094.71207.22
304. Kijima-Suda I, Toyoshima S, Itoh M, Furuhata K, Ogura H, Osawa T. Inhibition of sialyltransferases of murine lymphocytes by disaccharide nucleosides. Chem Pharm Bull (Tokyo) (1985) 33(2):730-9. doi:10.1248/cpb.33.730
305. Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, et al. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res (2011) 71(2):473-83. doi:10.1158/0008-5472.CAN-10-1303
306. Wu CY, Hsu CC, Chen ST, Tsai YC. Soyasaponin I, a potent and specific sialyltransferase inhibitor. Biochem Biophys Res Commun (2001) 284(2):466-9. doi:10.1006/bbrc.2001.5002
307. Hsu CC, Lin TW, Chang WW, Wu CY, Lo WH, Wang PH, et al. Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol (2005) 96(2):415-22. doi:10.1016/j.ygyno.2004.10.010
308. Chang WW, Yu CY, Lin TW, Wang PH, Tsai YC. Soyasaponin I decreases the expression of alpha2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. Biochem Biophys Res Commun (2006) 341(2):614-9. doi:10.1016/j.bbrc.2005.12.216
309. Chang KH, Lee L, Chen J, Li WS. Lithocholic acid analogues, new and potent alpha-2,3-sialyltransferase inhibitors. Chem Commun (Camb) (2006) 6:629-31. doi:10.1039/b514915k
310. Chiang CH, Wang CH, Chang HC, More SV, Li WS, Hung WC. A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signaling. J Cell Physiol (2010) 223(2):492-9. doi:10.1002/jcp.22068
311. Mare L, Trinchera M. Suppression of beta 1,3galactosyltransferase beta 3Gal-T5 in cancer cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines and sialyl-Lewis x on O-glycans. Eur J Biochem (2004) 271(1):186-94. doi:10.1046/j.1432-1033.2003.03919.x
312. Lin CH, Fan YY, Chen YY, Wang SH, Chen CI, Yu LC, et al. Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines. Glycobiology (2009) 19(4):418-27. doi:10.1093/glycob/cwn156
313. Hayashi N, Nakamori S, Okami J, Nagano H, Dono K, Umeshita K, et al. Association between expression levels of CA 19-9 and N-acetylglucosamine-beta, 1,3-galactosyltransferase 5 gene in human pancreatic cancer tissue. Pathobiology (2004) 71(1):26-34. doi:10.1159/000072959
314. Gao Y, Vlahakis JZ, Szarek WA, Brockhausen I. Selective inhibition of glycosyltransferases by bivalent imidazolium salts. Bioorg Med Chem (2013) 21(5):1305-11. doi:10.1016/j.bmc.2012.12.034
315. Nishihara S, Iwasaki H, Kaneko M, Tawada A, Ito M, Narimatsu H. Alpha1,3-fucosyltransferase 9 (FUT9; Fuc-TIX) preferentially fucosylates the distal GlcNAc residue of polylactosamine chain while the other four alpha1,3FUT members preferentially fucosylate the inner GlcNAc residue. FEBS Lett (1999) 462(3):289-94. doi:10.1016/S0014-5793(99)01549-5
316. Ogawa J, Inoue H, Koide S. Expression of alpha-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer. Cancer Res (1996) 56(2):325-9.
317. Martín-Satué M, Marrugat R, Cancelas JA, Blanco J. Enhanced expression of alpha(1,3)-fucosyltransferase genes correlates with E-selectin-mediated adhesion and metastatic potential of human lung adenocarcinoma cells. Cancer Res (1998) 58(7):1544-50.
318. Martin-Satue M, de Castellarnau C, Blanco J. Overexpression of alpha(1,3)-fucosyltransferase VII is sufficient for the acquisition of lung colonization phenotype in human lung adenocarcinoma HAL-24Luc cells. Br J Cancer (1999) 80(8):1169-74. doi:10.1038/sj.bjc.6690482
319. Hiraiwa N, Dohi T, Kawakami-Kimura N, Yumen M, Ohmori K, Maeda M, et al. Suppression of sialyl Lewis X expression and E-selectin-mediated cell adhesion in cultured human lymphoid cells by transfection of antisense cDNA of an alpha1 → 3 fucosyltransferase (Fuc-T VII). J Biol Chem (1996) 271(49):31556-61. doi:10.1074/jbc.271.49.31556
320. Padró M, Cobler L, Garrido M, de Bolós C. Down-regulation of FUT3 and FUT5 by shRNA alters Lewis antigens expression and reduces the adhesion capacities of gastric cancer cells. Biochim Biophys Acta (2011) 1810(12):1141-9. doi:10.1016/j.bbagen.2011.09.011
321. Carvalho AS, Harduin-Lepers A, Magalhães A, Machado E, Mendes N, Costa LT, et al. Differential expression of alpha-2,3-sialyltransferases and alpha-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells. Int J Biochem Cell Biol (2010) 42(1):80-9. doi:10.1016/j.biocel.2009.09.010
322. Guo Q, Guo B, Wang Y, Wu J, Jiang W, Zhao S, et al. Functional analysis of alpha 1,3/4-fucosyltransferase VI in human hepatocellular carcinoma cells. Biochem Biophys Res Commun (2012) 417(1):311-7. doi:10.1016/j.bbrc.2011.11.106
323. Li J, Guillebon AD, Hsu JW, Barthel SR, Dimitroff CJ, Lee YF, et al. Human fucosyltransferase 6 enables prostate cancer metastasis to bone. Br J Cancer (2013) 109(12):3014-22. doi:10.1038/bjc.2013.690
324. Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, et al. Development of orally active inhibitors of protein and cellular fucosylation. Proc Natl Acad Sci U S A (2013) 110(14):5404-9. doi:10.1073/pnas.1222263110
325. Zandberg WF, Kumarasamy J, Pinto BM, Vocadlo DJ. Metabolic inhibition of sialyl-Lewis X biosynthesis by 5-thiofucose remodels the cell surface and impairs selectin-mediated cell adhesion. J Biol Chem (2012) 287(47):40021-30. doi:10.1074/jbc.M112.403568
326. Shinoda K, Shitara K, Yoshihara Y, Kusano A, Uosaki Y, Ohta S, et al. Panosialins, inhibitors of an alpha1,3-fucosyltransferase Fuc-TVII, suppress the expression of selectin ligands on U937 cells. Glycoconj J (1998) 15(11):1079-83. doi:10.1023/A:1006953626578
327. Mong TK, Lee LV, Brown JR, Esko JD, Wong CH. Synthesis of N-acetyllactosamine derivatives with variation in the aglycon moiety for the study of inhibition of sialyl Lewis x expression. Chembiochem (2003) 4(9):835-40. doi:10.1002/cbic.200300650
328. Yu-Nong L, Daniel S, Sheng-Wei L, Sue-Ming C, Ting-Chien L, Yu-Ruei C. Chemoenzymatic synthesis of GDP-L-fucose derivatives as potent and selective alpha-1,3-fucosyltransferase inhibitors. Adv Synth Catal (2012) 354(9):1750-8. doi:10.1002/adsc.201100940
329. Burkart MD, Vincent SP, Düffels A, Murray BW, Ley SV, Wong CH. Chemo-enzymatic synthesis of fluorinated sugar nucleotide: useful mechanistic probes for glycosyltransferases. Bioorg Med Chem (2000) 8(8):1937-46. doi:10.1016/S0968-0896(00)00139-5
330. Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol (2012) 8(7):661-8. doi:10.1038/nchembio.999
331. Luengo JI, Gleason JG. Synthesis of C-fucopyranosyl analogs of Gdp-L-fucose as inhibitors of fucosyltransferases. Tetrahedron Lett (1992) 33(46):6911-4. doi:10.1016/S0040-4039(00)60893-6
332. Pasquarello C, Picasso S, Demange R, Malissard M, Berger EG, Vogel P. The C-disaccharide alpha-C(1 → 3)-mannopyranoside of N-acetylgalactosamine is an inhibitor of glycohydrolases and of human alpha-1,3-fucosyltransferase VI. its epimer alpha-(1 → 3)-mannopyranoside of N-acetyltalosamine is not. J Org Chem (2000) 65(14):4251-60. doi:10.1021/jo991952u
333. Vidal S, Bruyère I, Malleron A, Augé C, Praly JP. Non-isosteric C-glycosyl analogues of natural nucleotide diphosphate sugars as glycosyltransferase inhibitors. Bioorg Med Chem (2006) 14(21):7293-301. doi:10.1016/j.bmc.2006.06.057
334. Niu X, Fan X, Sun J, Ting P, Narula S, Lundell D. Inhibition of fucosyltransferase VII by gallic acid and its derivatives. Arch Biochem Biophys (2004) 425(1):51-7. doi:10.1016/j.abb.2004.02.039
335. Lin TW, Chang WW, Chen CC, Tsai YC. Stachybotrydial, a potent inhibitor of fucosyltransferase and sialyltransferase. Biochem Biophys Res Commun (2005) 331(4):953-7. doi:10.1016/j.bbrc.2005.03.232